Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.

La descripción de la empresa se muestra en inglés.

Visitar sitio web →

Estadísticas Clave

Capitalización: $2.79M
Ratio P/E: N/A
Máximo 52 Sem.: $5.60
Mínimo 52 Sem.: $0.72
Volumen Promedio: 332.81K
Beta: 1.87

Datos proporcionados por Yahoo Finance a través de yfinance. Actualizado diariamente.

Información de la Empresa

Industria: Biotecnología
Bolsa: NASDAQ
País: United States
Empleados: 52